Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Molecular profiling: an essential technology enabling personalized medicine in breast cancer.

Liu J, Li S, Dunker AK, Uversky VN.

Curr Drug Targets. 2012 Apr;13(4):541-54. Review.

PMID:
22250651
2.

Molecular predictors of local tumor control in early-stage breast cancer.

Miyamoto DT, Harris JR.

Semin Radiat Oncol. 2011 Jan;21(1):35-42. doi: 10.1016/j.semradonc.2010.08.005. Review.

PMID:
21134652
3.

Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.

Dobbe E, Gurney K, Kiekow S, Lafferty JS, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 1;65(1):23-8. Review.

PMID:
18159035
4.

[Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting].

Gonçalves A, Moretta J, Eisinger F, Bertucci F.

Bull Cancer. 2013 Dec;100(12):1295-310. doi: 10.1684/bdc.2013.1856. Review. French.

PMID:
24225763
5.

Personalized treatment of early-stage breast cancer: present concepts and future directions.

Harbeck N, Salem M, Nitz U, Gluz O, Liedtke C.

Cancer Treat Rev. 2010 Dec;36(8):584-94. doi: 10.1016/j.ctrv.2010.04.007. Epub 2010 Jun 2. Review.

PMID:
20554119
6.

DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer.

Germain DR, Graham K, Glubrecht DD, Hugh JC, Mackey JR, Godbout R.

Breast Cancer Res Treat. 2011 May;127(1):53-63. doi: 10.1007/s10549-010-0943-7. Epub 2010 May 25.

PMID:
20499159
7.
8.

Predictive factors for local recurrence in breast cancer.

van der Leij F, Elkhuizen PH, Bartelink H, van de Vijver MJ.

Semin Radiat Oncol. 2012 Apr;22(2):100-7. doi: 10.1016/j.semradonc.2011.12.001. Review.

PMID:
22385917
9.

Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.

Huber KE, Carey LA, Wazer DE.

Semin Radiat Oncol. 2009 Oct;19(4):204-10. doi: 10.1016/j.semradonc.2009.05.004. Review.

PMID:
19732684
10.

Genomic predictors of outcome and treatment response in breast cancer.

Dunn L, Demichele A.

Mol Diagn Ther. 2009;13(2):73-90. doi: 10.2165/01250444-200913020-00002. Review.

PMID:
19537843
11.
12.

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.

Clin Cancer Res. 2005 May 1;11(9):3315-9.

13.
14.

p53 as an independent prognostic marker in lymph node-negative breast cancer patients.

Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U.

J Natl Cancer Inst. 1993 Jun 16;85(12):965-70.

PMID:
8496982
15.

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D.

J Clin Oncol. 2004 May 1;22(9):1564-71. Epub 2004 Mar 29.

PMID:
15051756
16.

Personalized therapy in breast cancer.

Marmé F, Schneeweiss A.

Onkologie. 2012;35 Suppl 1:28-33. doi: 10.1159/000334973. Epub 2012 Jan 20.

PMID:
22286585
17.

Gene expression profiling in breast cancer.

Morris SR, Carey LA.

Curr Opin Oncol. 2007 Nov;19(6):547-51. Review.

PMID:
17906450
18.

Personalized medicine: present and future of breast cancer management.

Sabatier R, Gonçalves A, Bertucci F.

Crit Rev Oncol Hematol. 2014 Sep;91(3):223-33. doi: 10.1016/j.critrevonc.2014.03.002. Epub 2014 Mar 26. Review.

PMID:
24725667
19.

Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.

Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ.

Ann Surg. 1995 Jun;221(6):706-18; discussion 718-20.

20.

Personalized medicine: the road ahead.

Mehta R, Jain RK, Badve S.

Clin Breast Cancer. 2011 Mar;11(1):20-6. doi: 10.3816/CBC.2011.n.004. Review.

PMID:
21421518

Supplemental Content

Support Center